TIAA CREF Investment Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
– Sell
-370
Closed -$34K – 3052
2017
Q4
$34K Hold
370
– – ﹤0.01% 3061
2017
Q3
$56K Buy
370
+77
+26% +$8.06K ﹤0.01% 3077
2017
Q2
$30K Buy
+293
New +$33.4K ﹤0.01% 3125
2016
Q2
– Sell
-451
Closed -$42K – 3182
2016
Q1
$42K Buy
+451
New +$39.9K ﹤0.01% 3070

Other funds holding IMDX

TIAA CREF Investment Management's IMDX Position: Q1 2018 in Review

TIAA CREF Investment Management sold out of Insight Molecular Diagnostics (IMDX) in Q1 2018, closing a stake of 370 shares — an estimated $34K sold.

TIAA CREF Investment Management first reported a position in IMDX in Q1 2016 and held it in 4 quarters. The position peaked at $56K in Q3 2017. 39 funds tracked by Wall St. Rank hold IMDX as of Q1 2018.

  • TIAA CREF Investment Management reported no remaining Insight Molecular Diagnostics position as of Q1 2018 after selling out during the quarter.
  • TIAA CREF Investment Management sold 370 Insight Molecular Diagnostics shares in Q1 2018, an estimated $34K.
  • TIAA CREF Investment Management first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 4 quarters.
  • TIAA CREF Investment Management's Insight Molecular Diagnostics position peaked at $56K in Q3 2017.
  • 39 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2018.

Based on TIAA CREF Investment Management's 13F filing for Q1 2018, filed 14 May 2018.